Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS-AF
2014-003702-33Phase 4Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of spironolactone in Atrial fibrillation (AFib) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by University of Birmingham. Primary endpoint: Improvement in exercise tolerance at 2 years. Started Jul 2015; status: completed.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2014-003702-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003702-33.